Fundz

Startup Using Machine Learning To Find New Medicines Raises £38M

PRIVATEOct 20, 2022

Amount Raised

£38 Million

Round Type

Funding Round

OxfordBiotechnologyTherapeutics

Description

Biotech startup Nucleome Therapeutics has raised £37.5m in an oversubscribed Series A round to discover new medicines by decoding the human genome.

Quick answer

Nucleome Therapeutics raised £38 Million in a Funding Round round, dated October 20, 2022. Nucleome Therapeutics is based in Oxford, England, United Kingdom.

How much did Nucleome Therapeutics raise?
Nucleome Therapeutics raised £38 Million in a Funding Round round on October 20, 2022.
What does Nucleome Therapeutics do?
Nucleome is an immunology company tackling the root causes of disease through a revolutionary new approach to solving human genetics.
Where is Nucleome Therapeutics based and how big is it?
Nucleome Therapeutics is based in Oxford, England, United Kingdom.
Who are the decision-makers at Nucleome Therapeutics?
Fundz holds 1 contact at Nucleome Therapeutics. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at Nucleome Therapeutics, and when

A new round usually means Nucleome Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Nucleome Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Nucleome Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Nucleome Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Nucleome Therapeutics

Location

Oxford, England, United Kingdom

About

Nucleome is an immunology company tackling the root causes of disease through a revolutionary new approach to solving human genetics. Nucleome has a deep molecular understanding of the function and importance of the non-coding genome and how variation within it causes disease. The Company has created transformative 3D genomics technology to link disease-associated genetic variants with the genes they dysregulate in disease. At the core of this, is the ability to read 3D interactions in the non-coding genome with a precision and scale that is unique in both industry and academia.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Nucleome Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Nucleome Therapeutics's next move

See what Strategic adds

Nucleome Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.